Lenalidomide

Lenalidomide, the active ingredient in this product, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for systemic use. It is indicated for treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in appropriate patients. It is used under specialist supervision in adult patients with these hematologic malignancies.

GNH USA supplies Lenalidomide as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Lenalidomide is employed in hematologic oncology to target malignant plasma cells and related disorders, offering disease-modifying benefits. - Multiple myeloma: improves disease control, prolongs progression‑free and overall survival, and enhances response rates in relapsed or refractory patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence, corrects cytopenias, and can lead to durable hematologic improvement. - Mantle cell lymphoma: contributes to overall response when combined with other agents, supporting disease control in relapsed settings.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Fatigue - Nausea - Diarrhea - Low blood counts (neutropenia, anemia, thrombocytopenia) Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Severe neutropenia with infection risk - Secondary primary malignancies

Before and during therapy, clinicians should observe several safety measures. - Monitor blood counts regularly: detect neutropenia, anemia, thrombocytopenia early. - Assess thrombotic risk before initiating therapy: consider prophylactic anticoagulation if indicated. - Avoid use in pregnant women: teratogenic risk classified as Category X. - Adjust dose in patients with severe renal impairment: follow prescriber guidance. - Discontinue if severe skin reactions or organ toxicity occur: seek immediate medical attention. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Lenalidomide can interact with several medicines, requiring careful management. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants (warfarin, DOACs): increased risk of thrombosis or bleeding; monitor closely. - Immunosuppressants (e.g., cyclosporine): may enhance toxicity. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma levels. - Live attenuated vaccines: reduced efficacy, consider alternatives. - NSAIDs and aspirin: may exacerbate thrombocytopenia.